title: Immunotherapy of head and neck cancer: current and future considerations.
abstract: Patients with head and neck squamous cell carcinoma (HNSCC) are at considerable risk for death, with 5-year relative survival rates of approximately 60%. The profound multifaceted deficiencies in cell-mediated immunity that persist in most patients after treatment may be related to the high rates of treatment failure and second primary malignancies. Radiotherapy and chemoradiotherapy commonly have severe acute and long-term side effects on immune responses. The development of immunotherapies reflects growing awareness that certain immune system deficiencies specific to HNSCC and some other cancers may contribute to the poor long-term outcomes. Systemic cell-mediated immunotherapy is intended to activate the entire immune system and mount a systemic and/or locoregional antitumor response. The delivery of cytokines, either by single cytokines, for example, interleukin-2, interleukin-12, interferon-gamma, interferon-alpha, or by a biologic mix of multiple cytokines, such as IRX-2, may result in tumor rejection and durable immune responses. Targeted immunotherapy makes use of monoclonal antibodies or vaccines. All immunotherapies for HNSCC except cetuximab remain investigational, but a number of agents whose efficacy and tolerability are promising have entered phase 2 or phase 3 development.
authors.affiliation: Department of Head and Neck Surgery, Greek Anticancer Institute, Saint Savvas Hospital, 171 Alexandras Avenue, 115 22 Athens, Greece.
authors.forename: Alexander D
authors.initials: AD
authors.lastname: Rapidis
authors.forename: Gregory T
authors.initials: GT
authors.lastname: Wolf
references.citation: Otolaryngol Clin North Am. 1985 Aug;18(3):367-88
references.pmid: 3900876
references.citation: Cancer Res. 2002 Sep 1;62(17):5049-57
references.pmid: 12208760
references.citation: Mod Pathol. 2005 Apr;18(4):485-94
references.pmid: 15475932
references.citation: Clin Cancer Res. 2000 Mar;6(3):979-86
references.pmid: 10741724
references.citation: Crit Rev Oral Biol Med. 2003;14(5):345-62
references.pmid: 14530303
references.citation: Cancer Immunol Immunother. 2006 Apr;55(4):451-8
references.pmid: 16034562
references.citation: Anticancer Drugs. 2006 Jan;17(1):1-12
references.pmid: 16317284
references.citation: Biochem Biophys Res Commun. 2004 Oct 8;323(1):156-62
references.pmid: 15351715
references.citation: Arch Otolaryngol Head Neck Surg. 1992 May;118(5):526-8
references.pmid: 1571128
references.citation: Biol Pharm Bull. 2007 Jan;30(1):150-6
references.pmid: 17202676
references.citation: Arch Otolaryngol Head Neck Surg. 1987 Nov;113(11):1200-6
references.pmid: 3499156
references.citation: Cancer Immunol Immunother. 2004 May;53(5):375-82
references.pmid: 14634795
references.citation: N Engl J Med. 2003 Jan 16;348(3):203-13
references.pmid: 12529460
references.citation: Cancer. 2002 Jul 1;95(1):90-7
references.pmid: 12115321
references.citation: Jpn J Clin Oncol. 2007 Feb;37(2):140-5
references.pmid: 17255158
references.citation: Oncol Rep. 2005 Jan;13(1):3-10
references.pmid: 15583794
references.citation: Hum Immunol. 2001 Apr;62(4):332-41
references.pmid: 11295465
references.citation: Clin Cancer Res. 2005 Feb 1;11(3):1010-20
references.pmid: 15709166
references.citation: Curr Opin Pharmacol. 2002 Aug;2(4):382-7
references.pmid: 12127870
references.citation: Cancer. 1993 Apr 1;71(7):2326-31
references.pmid: 8453554
references.citation: N Engl J Med. 2007 May 10;356(19):1944-56
references.pmid: 17494927
references.citation: Clin Cancer Res. 2000 Jul;6(7):2794-802
references.pmid: 10914726
references.citation: J Immunother. 2008 Nov-Dec;31(9):885-95
references.pmid: 18832999
references.citation: Curr Opin Oncol. 2005 May;17(3):212-7
references.pmid: 15818163
references.citation: J Nucl Med. 2005 Apr;46(4):620-33
references.pmid: 15809485
references.citation: Cancer Biol Ther. 2006 Dec;5(12):1624-31
references.pmid: 17172816
references.citation: Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1225-31
references.pmid: 11031409
references.citation: Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8
references.pmid: 9050879
references.citation: Rev Recent Clin Trials. 2008 Sep;3(3):156-66
references.pmid: 18782074
references.citation: Expert Opin Emerg Drugs. 2006 Sep;11(3):461-7
references.pmid: 16939385
references.citation: Arch Otolaryngol Head Neck Surg. 2005 Apr;131(4):304-7
references.pmid: 15837897
references.citation: J Biomed Sci. 2008 May;15(3):275-89
references.pmid: 18392689
references.citation: Anticancer Res. 2004 Mar-Apr;24(2B):973-9
references.pmid: 15161052
references.citation: J Natl Cancer Inst. 2000 May 3;92(9):709-20
references.pmid: 10793107
references.citation: J Immunother. 2007 Sep;30(6):624-33
references.pmid: 17667526
references.citation: Clin Cancer Res. 2004 Apr 15;10(8):2626-35
references.pmid: 15102664
references.citation: Int J Cancer. 1995 Oct 20;64(5):304-8
references.pmid: 7591301
references.citation: Adv Otorhinolaryngol. 2005;62:151-60
references.pmid: 15608425
references.citation: Br J Cancer. 2005 Apr 25;92(8):1341-8
references.pmid: 15846296
references.citation: J Clin Oncol. 2004 May 1;22(9):1646-54
references.pmid: 15117987
references.citation: Curr Oncol Rep. 2001 Jan;3(1):46-55
references.pmid: 11123869
references.citation: Arch Otolaryngol Head Neck Surg. 1990 Nov;116(11):1271-7
references.pmid: 2122909
references.citation: Cancer Res. 1992 Sep 1;52(17):4832-6
references.pmid: 1324797
references.citation: Int J Cancer. 2007 Nov 15;121(10):2181-91
references.pmid: 17597103
references.citation: J Immunother. 2004 Mar-Apr;27(2):124-35
references.pmid: 14770084
references.citation: Clin Exp Metastasis. 2000;18(2):155-61
references.pmid: 11235991
references.citation: J Clin Oncol. 2005 Feb 1;23(4):720-31
references.pmid: 15613691
references.citation: Clin Cancer Res. 2000 Jan;6(1):24-33
references.pmid: 10656428
references.citation: Laryngoscope. 2005 Mar;115(3):391-404
references.pmid: 15744147
references.citation: Curr Opin Oncol. 2001 May;13(3):183-8
references.pmid: 11307062
references.citation: Head Neck. 2008 Feb;30(2):251-61
references.pmid: 18172882
references.citation: Curr Oncol Rep. 2009 Mar;11(2):156-62
references.pmid: 19216848
references.citation: Cancer Res. 2003 Mar 15;63(6):1188-91
references.pmid: 12649174
references.citation: Cancer Res. 1997 Oct 15;57(20):4593-9
references.pmid: 9377574
references.citation: Arch Pathol Lab Med. 1998 May;122(5):447-54
references.pmid: 9593347
references.citation: N Engl J Med. 2008 Sep 11;359(11):1143-54
references.pmid: 18784104
references.citation: Cancer Res. 2005 Dec 1;65(23):11146-55
references.pmid: 16322265
references.citation: Cancer Biol Ther. 2006 Sep;5(9):1226-7
references.pmid: 17021387
references.citation: Int Immunopharmacol. 2003 Aug;3(8):1061-71
references.pmid: 12860163
references.citation: Clin Cancer Res. 2006 Nov 15;12(22):6737-47
references.pmid: 17121894
references.citation: Head Neck. 2006 May;28(5):462-70
references.pmid: 16284974
references.citation: Head Neck. 2003 Mar;25(3):198-209
references.pmid: 12599287
references.citation: FASEB J. 2005 May;19(7):780-2
references.pmid: 15774576
references.citation: Clin Adv Hematol Oncol. 2005 Feb;3(2):92-3
references.pmid: 16166973
references.citation: Chemotherapy. 2002 Sep;48(4):211-6
references.pmid: 12218269
references.citation: J Clin Oncol. 2005 Dec 10;23(35):8942-9
references.pmid: 16204009
references.citation: Nat Med. 1996 Oct;2(10):1096-103
references.pmid: 8837607
references.citation: Head Neck. 2003 Jun;25(6):457-63
references.pmid: 12784237
references.citation: Int Immunopharmacol. 2003 Aug;3(8):1083-91
references.pmid: 12860165
references.citation: J Cancer Res Clin Oncol. 2005 Sep;131(9):624-30
references.pmid: 16044346
references.citation: Br J Cancer. 1996 Jan;73(2):228-35
references.pmid: 8546911
references.citation: Laryngoscope. 2003 May;113(5):888-91
references.pmid: 12792328
references.citation: J Clin Oncol. 2006 Apr 10;24(11):1705-11
references.pmid: 16549819
references.citation: Important Adv Oncol. 1992;:93-109
references.pmid: 1316312
references.citation: Cancer. 2001 Jun 1;91(11):2136-47
references.pmid: 11391595